Limerick Biopharma Announces Positive Phase 1b for Lim-0705 to prevent drug-related toxicity, transplant, tacrolimus

The data in our first phase, we were pleased that the LIM-0705 is effective in redistributing tacrolimus on the major organs that are vulnerable to toxicity, said Michael Chang, vice president of Limerick Research and Development. These new data are the first evidence from human studies that the use of our drugs may reduce the physiological consequences of tacrolimus.Limerick BioPharma, Inc., a developer of innovative therapies that help the cells to pump unwanted or toxic substances, will announce new results from human trials of its flagship product, the MFR-0705, 23 International Congress of the Transplantation Society, Vancouver , Canada, in an oral presentation August 19, 2010. Results will be presented by Dr. Brennan, Professor of Medicine and director of transplant nephrology at the University of Washington School of Medicine in St. Louis.

And ‘being developed as adjunctive therapy with tacrolimus, a calcineurin inhibitor used as an immunosuppressant for transplant surgery. Although tacrolimus is the gold standard in preventing the rejection of solid organs, the pancreas produces negative effects in the brain and kidneys, which negatively affects the survival of the graft and the host. LIM-0705 is designed to protect the tissues from the adverse effects of tacrolimus, while maintaining its anti-rejection medications.

, and Rabi Tawil, MD, Leiden University Medical Center and the FSH and the Centre for Neuromuscular Research fields at the University of Rochester, respectively.’.

The work will lead to new approaches to therapy and new perspectives on human evolution.

Comments are closed.